Latest news

• Dupixent gains can’t keep Sanofi on a growth track

  First launched for atopic dermatitis in 2016, label extensions to include adolescent AD patients as well as asthma and chronic rhinosinusitis with nasal polyps helped sales of Regeneron-partnered Dupixent (dupilumab)

• Sanofi/Regeneron wins another EU approval for Dupixent

  This included a 57% and 51% improvement in nasal congestion/obstruction severity, compared to 19% and 15% in the placebo groups in SINUS-24 and SINUS-52. ... It also demonstrated a 33% and 27% reduction in participant’s nasal polyps score compared to a

• FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

  Nasal polyps can lead to loss of smell and often patients require surgery to remove the polyps,” said the agency’s head of pulmonary, allergy and rheumatology products Sally Seymour. ... Trials of the drug in nasal polyps have showed that it could

• Sanofi's Dupixent gains asthma approval in Europe

  The companies have big plans for the drug, researching its clinical benefit in other diseases driven by allergic and other type 2 inflammation, including chronic rhinosinusitis with nasal polyps. ... A phase 3 showed that Dupixent significantly improved

• Dupixent helps put Sanofi back on growth track

  Meanwhile, Sanofi and development partner Regeneron have also just reported new data in patients with rhinosinusitis and nasal polyps which could expand its use further.